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Background. Prospective studies about the reversibility of tenofovir disoproxil fumarate- (TDF-) related renal impairment remain
scarce.Methods. This is an observational prospective study including all patients that presented at our HIV Unit who interrupted
TDF owing to nephrotoxicity.We assessed the evolution of renal parameters after discontinuation of this drug.Results. We included
59 patients, who were followed up for 72 weeks. Most were male (41, 69.5%), median (IQR) age was 53 (44; 58) years, and median
time receiving TDF-containing regimens was 55.4 (28; 87.7) months. Most patients were receiving PI-based treatments (67%).
At the final visit, most of the subjects showed complete recovery (35, 59.3%) or improvement (13 subjects, 22%). Significant
improvements were observed in creatinine levels (from 84.9 [73.8; 97.5] to 78 [69.6; 91]𝜇mol/L, 𝑝 = 0.013), estimated glomerular
filtration rate (eGFR, CKD EPI equation, from 87.7 [67; 99] to 89.9 [73.6; 99.3]mL/min/1.73m2, 𝑝 = 0.017), and number of
patients with eGFR <60mL/min/1.73m2 (from 9 [15.3%] to 1 [1.7%], 𝑝 = 0.031). A trend toward significance was observed in
abnormal urine proteinuria/creatinine ratio (from 22 [37%] to 8 [13.6%], 𝑝 = 0.057). Conclusions. Our results corroborate the high
frequency of complete or partial renal recovery in patients receiving TDF-containing regimens who discontinued therapy owing
to nephrotoxicity.
1. Introduction
Nephrotoxicity associated with tenofovir disoproxil fumarate
(TDF) has been well characterized in clinical and study
cohorts [1, 2], although prospective studies assessing TDF-
related renal toxicity in clinical practice are scarce. Very often,
discontinuation of TDF does not lead to complete reversibil-
ity of renal damage [3, 4]. The principal aim of this prospec-
tive study was to assess changes in laboratory values in a coh-
ort of patients who interrupted TDF owing to nephrotoxicity.
2. Materials and Methods
2.1. Study Design and Patients. We conducted an observa-
tional prospective study including all patients that presented
at our HIV Unit who interrupted TDF owing to TDF-related
nephrotoxicity.
The patients had received a TDF-containing regimen for
at least 3 months. All patients had normal renal laboratory
values at baseline of TDF-including treatment, presented
nephrotoxicity during treatment, and discontinued TDF
owing to abnormal laboratory values. In order to fully
evaluate changes in renal laboratory values, we chose to
follow up patients for 18 months (72 weeks) after interruption
of TDF, based on the median time to normalization of renal
values in a previous study (17 months) [4].
The study was approved by the Institutional Review
Board (code EO-12-036). All patients provided their written
informed consent.
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2.2. Objectives. The primary objective of the study was to
assess changes in renal markers when TDF was discontinued
in patients who developed renal impairment while taking
this drug. We collected the number of patients whose renal
function values returned to normal and the time to com-
plete recovery, the number of patients whose renal function
improved without achieving normal values, and the number
of cases of irreversibility.
The secondary objective was to identify factors that
predisposed to complete recovery.
2.3. Measurements and Definitions. Renal impairment was
defined as at least 1 of the following 3 criteria: (i) estimated
glomerular filtration rate (eGFR) <60mL/min/1.73m2 in 2
consecutive measurements (calculated using the Chronic
Kidney Disease Epidemiology Collaboration [CKD EPI]
equation) [5], (ii) a ≥2-fold increase in serum creatinine
above baseline values, and (iii) at least 2 determinations
with altered urine protein/creatinine ratio and urine albu-
min/creatinine ratio, low levels of serum phosphate, and
presence of glycosuria without hyperglycemia or hematuria.
All the abnormalities in the patients selected were detected
in at least two consecutive determinations for a period of 3
months or more previous to the baseline visit. Subjects with
extra renal causes of glycosuria and hypophosphatemia were
excluded from the study.
The normal local reference values were as follows: eGFR
≥90mL/min/1.73m2; creatinine ≤106 𝜇mol/L; urine albu-
min/creatinine ratio ≤30mg/g; urine protein/creatinine ratio
≤200mg/g; serumphosphate 0.87–1.50mmol/L; and negative
glycosuria and qualitative hematuria.
Renal outcome after discontinuation of TDF was classi-
fied as normalization, improvement, or irreversible damage,
as described elsewhere [4]. Briefly, the return to the base-
line normal values in all renal parameters was considered
normalization. An improvement in altered renal parameters
but without achieving normal values was defined as improve-
ment. Finally, renal damage was considered irreversible when
the patient did not present any improvement in any of
the altered parameters observed at discontinuation of TDF.
Time to normalization was considered the first time at
which patients returned to normal range values for all renal
parameters after interruption of TDF. Time to improvement
was considered the first time at which patients achieved
consistently better values in any renal parameter.
Demographic data, comorbidities, and HIV-related data
were also collected from the patient’s clinical history. Viro-
logical, immunological, and renal data were collected imme-
diately before discontinuation of TDF and every 3 months
thereafter until 72 weeks after discontinuation. All determi-
nations were performed under fasting conditions.
2.4. Statistical Analyses. The mean (SD), median (IQR), and
frequency (%) were used to describe patients’ characteristics,
as appropriate.
A descriptive data analysis was performed in order to
identify time to normalization or time tomaximum improve-
ment.
A subanalysis using Kaplan-Meier survival analysis was
performed in order to detect the first time for each patient
where all the altered values return to normality.
Univariant and multivariant Cox regression models were
performed and included the following variables: gender,
age, hepatitis coinfection, time since diagnosis of HIV, viral
load, CD4 T-cell count at the beginning and end of the
TDF-containing regimen, nadir CD4 T-cell count, months
on antiretroviral treatment, months on protease inhibitors
and TDF, type of change in antiretroviral therapy, diabetes
mellitus, and arterial hypertension.
All analyses were performed using SPSS version 15.0
(SPSS Inc., Chicago, Illinois, USA) and the R software pack-
age (version 3.2.1). A 𝑝 value of less than 0.05 was considered
statistically significant.
3. Results
The study population comprised 60 patients. One patient was
excluded owing to missing data. Most patients were male (41,
69.5%), median (IQR) age was 53 (44; 58) years, and median
time onTDF-containing regimenswas 55.4 (28; 87.7)months.
Most of the patients were receiving protease inhibitor- (PI-)
based regimens (67%). A total of 19 patients (32%) were
coinfected with hepatitis, 14 (24%) had arterial hyperten-
sion, and 8 (13.6%) had diabetes mellitus (supplementary
web table in Supplementary Material available online at
http://dx.doi.org/10.1155/2016/4380845).
The most frequent renal abnormality before discontinua-
tion of TDF was altered proteinuria/creatinine ratio (37%),
which was mild in most cases (69.5%); 5 patients (6.7%)
presented occasional proteinuria >1 g, and only 2 patients
(3%) had sustained proteinuria >1 g.
After interruption of TDF, a significant improvement
was observed in creatinine and eGFR values. The number
of patients with an eGFR <60mL/min/1.73m2 decreased
significantly. A trend toward improvement was observed
in the percentage of patients with an abnormal urine pro-
tein/creatinine ratio. The results are summarized in Table 1.
Kaplan-Meier results showed that all patients returned
to normal values in all the altered parameters at any time
of the follow-up with the exception of two subjects (96.6%;
see Figure 1). Median (IQR) time to normal values was 12
(4; 24) weeks. From the 2 patients whose values did not
return to normal, one had abnormal eGFR at baseline that
improved but without reaching normal values (from 66 to
80mL/min/1.73m2), while proteinuria returned to normal
values (from 220mg/gr to 160mg/gr at the final visit). The
other subject only showed a slight improvement in protein-
uria/creatinine ratio (from 320 to 240mg/gr). Nevertheless,
not all the patientsmaintained the total normalization during
the follow-up and, at the final visit, 35 patients had normality
in all the parameters (59.3%); improvement but without
complete recovery was detected in 13 patients (22%); and,
finally, 11 subjects did not show improvement (18.7%).
The univariate analysis revealed an inverse correlation
between age and renal recovery (hazard ratio [HR] = 0.973;
𝑝 = 0.046) and a trend toward a positive correlation between
patients who discontinued TDF only (without changing their
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Table 1: Changes in laboratory values.
Baseline End offollow-up 𝑝 value
Creatinine, median (IQR),
𝜇mol/L
84.9 (73.8;
97.5) 78 (69.9; 91) 0.013
Abnormal creatinine values,
n (%) 10 (16.9) 3 (5.1%) 0.125
eGFR (CKD EPI), median,
(IQR), mL/min/1.73m2 87.7 (67; 99)
89.9 (73.6;
99.3) 0.017
eGFR (CKP EPI), n (%)
<60mL/min/1.73m2 9 (15.3%) 1 (1.7%) 0.031
eGFR (CKP EPI), n (%)
≥90mL/min/1.73m2 25 (42.4%) 23 (39%) 0.549
Serum phosphate levels,
mmol/L, median (IQR)
1.02 (0.9;
1.13)
1.00 (0.9.;
1.5) 0.632
Abnormal phosphate levels,
n (%) 12 (23%) 9 (21%) 0.319
Urine albumin/creatinine
ratio (mg/g) 18.4 (3; 56) 8.7 (1.7; 38) 0.446
Abnormal urine
albumin/creatinine ratio, n
(%)
11 (18.6%) 8 (13.6%) 1
Urine protein/creatinine
ratio (mg/g)
180.5 (95;
322) 85 (69; 198) 0.118
Abnormal urine
protein/creatinine ratio, n
(%)
22 (37%) 8 (13.6%) 0.057
Urine hemoglobin 19 (32.2%) 11 (18.6%) 0.068
Glycosuria, n (%) 4 (6.8%) 0 0.18
TDF: tenofovir disoproxil fumarate; IQR: interquartile range; eGFR: esti-
mated glomerular filtration rate; CKD EPI: Chronic Kidney Disease Epi-
demiology Collaboration; 𝑛: number of patients.
other drugs) (HR = 1.57, 𝑝 = 0.10) and those who switched
TDF to abacavir (HR = 0.652, 𝑝 = 0.12). When these 3
factors were included in the multiple Cox model, the inverse
correlation with recovery was only maintained for age (HR =
0.972, 𝑝 = 0.032).
The characteristics of the patients whose renal values
recovered fully and rapidly (<6 months after the change in
treatment) were comparedwith thosewhose values recovered
later and/or incompletely. The associated factors were age
(median [IQR]: 49.5 [43; 58] years in early normalization
versus 55 [50; 62] in >6 months to normalization [𝑝 = 0.034;
OR = 0.937; 95%CI, 0.883; 0.995]) and time onHIV infection
(151.4 [81.3; 212.1] months versus 199.3 [151.6; 264.3] months
[𝑝 = 0.049; OR = 0.994; 95%CI, 0.988; 1.00]).The differences
for other variables, such as time on antiretroviral treatment,
time on TDF, and comorbidities, did not reach statistical
significance.
4. Discussion
This is one of the few prospective studies that focus specifi-
cally on assessing progression of renal abnormalities, includ-
ing urinary markers, after withdrawal of TDF. Consistent
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Figure 1: Kaplan-Meier survival analysis. First time to achieve total
normalization in all parameters (weeks). Median: 12, IQR (4; 24).
with data from retrospective [3, 4] and cross-sectional studies
[6], our findings show that proteinuria is the most common
TDF-related renal abnormality. However, in contrast, we
found that renal abnormalities resolved fully in most of the
patients.
Although median proteinuria values before interruption
of TDF were above normal levels, abnormalities were mild
in most patients (in fact, only 2 patients had a sustained
urine protein/creatinine ratio >1 g/g). This finding could
explain why interrupting TDF did not lead to a statistically
significant improvement in proteinuria values, although val-
ues returned to normal in most of the patients after the
interruption.
The main TDF-related toxicity is a proximal tubular
dysfunction, while altered GFR and advanced renal disease
seem to be infrequent [7]. Several mechanisms could play a
role in the toxicity of the drug. Tenofovir is excreted from
the tubular cell by a combination of glomerular filtration
and active tubular secretion; the drug entry to the cell
through the basolateral membrane involves organic anion
transporters (OATs)mainlyOAT1. Subsequently, its secretion
to the tubular lumen is an active process mediated by protein
transporters that included multidrug-resistance protein 2
(MRP2) [8]. Since the toxicity seems to be related to the
intracellular concentration of the drug [9], by inhibition of
mitochondrial DNA replication in proximal tubular cells
and cellular apoptosis [10, 11], the concomitant use of PIs
blocks this step and increases the intracellular concentration
of TDF [12] and could relate to an increase in TDF-related
nephrotoxicity.
Finally, a high plasma TDF concentration has been also
correlated with an increase in nephrotoxicity [13, 14], and
this fact occurs more frequently with the concomitant use of
boosted PIs [15].
Although most of our patients were under PIs containing
strategies, a considerable proportion of our subjects return
to normal values, supporting the hypothesis of a functional
alteration, but not necessarily structural defects in tubular
cells [16]. Nevertheless, in some cases, the subjects did not
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maintain the complete recovery through the follow-up. This
fact could be related to the multifactorial nature of these
alterations, or to some intercurrent process.
A previous retrospective study of 183 patients performed
in our unit [4] showed that laboratory values returned to
normal in almost 60% of patients, although in the remaining
cases values partially improved or did not improve after
interruption of TDF. When we assessed the same markers
in this prospective study, similar results were shown in our
patients. Guidelines published in recent years recommend
routine monitoring of urine and renal values among patients
receiving TDF-based therapy [17] so that nephrotoxicity can
be detected quickly and the drug discontinued early to enable
fast and complete recovery in a large proportion of subjects
under TDF-containing strategies.
We found that renal values reversed early in younger
people and in those infected for a shorter time. However,
even though the median age of our patients was 53 years and
the frequency of hypertension or diabetes was relatively high
(24% and 14%, resp.), renal recovery was complete in most of
them. In addition, more than two-thirds were concomitantly
receiving a ritonavir-boosted PI, which is known to increase
the risk of toxicity.
Our data confirm that TDF-induced renal damage
resolves in a considerable proportion of patients, even in
middle-aged patients who had received TDF for as long as
88 months (more than 7 years). Early detection of renal
impairment in clinical practice is essential for a complete and
rapid recovery.
A newprodrug of tenofovir, tenofovir alafenamide, (TAF)
will be soon available. TAF seems to have a better renal profile
than TDF [18]. However, it is still unclear whether this benefit
will be maintained in the case of concomitant use of other
antiretroviral agents that affect renal laboratory values, such
as PIs, or in the long term (data available with TAF until
96 weeks) [19]. While waiting for this new agent to become
available, detailed knowledge of TDF-related nephrotoxicity
and its reversibility will help us to better select the most
adequate antiretroviral agent for each patient and prevent
permanent renal damage.
Our study is limited by the small number of patients
included. However, we report the real prevalence of TDF-
related renal toxicity in our clinical practice over 18 months.
Even with this limitation, our results are robust and add to
data from retrospective studies.
In conclusion, we highlight the low percentage of
patients taking TDF who experienced irreversible nephro-
toxicity and the importance of monitoring urine markers
in these patients. Appropriate monitoring and early detec-
tion of renal abnormalities can ensure complete recovery
of kidney impairment very quickly after the interruption
of TDF in most of the subjects. Our findings show that
TDF-related nephrotoxicity could be reversible, even in
middle-aged individuals who have been receiving TDF for
almost 2 years.
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